About: Transmission genetics of drug-resistant hepatitis C virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Transmission genetics of drug-resistant hepatitis C virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Transmission genetics of drug-resistant hepatitis C virus
Creator	Kirkegaard, Karla Van Buuren, Nicholas Richardson, Christopher Tellinghuisen, Timothy
Source	Medline; PMC
abstract	Antiviral development is plagued by drug resistance and genetic barriers to resistance are needed. For HIV and hepatitis C virus (HCV), combination therapy has proved life-saving. The targets of direct-acting antivirals for HCV infection are NS3/4A protease, NS5A phosphoprotein and NS5B polymerase. Differential visualization of drug-resistant and -susceptible RNA genomes within cells revealed that resistant variants of NS3/4A protease and NS5A phosphoprotein are cis-dominant, ensuring their direct selection from complex environments. Confocal microscopy revealed that RNA replication complexes are genome-specific, rationalizing the non-interaction of wild-type and variant products. No HCV antivirals yet display the dominance of drug susceptibility shown for capsid proteins of other viruses. However, effective inhibitors of HCV polymerase exact such high fitness costs for drug resistance that stable genome selection is not observed. Barriers to drug resistance vary with target biochemistry and detailed analysis of these barriers should lead to the use of fewer drugs.
has issue date	2018-03-28(xsd:dateTime)
bibo:doi	10.7554/elife.32579
bibo:pmid	29589830
has license	cc-by
sha1sum (hex)	3cf94195ef1930e200e2e391517d90644ab108a1
schema:url	https://doi.org/10.7554/elife.32579
resource representing a document's title	Transmission genetics of drug-resistant hepatitis C virus
has PubMed Central identifier	PMC5916564
has PubMed identifier	29589830
schema:publication	eLife
resource representing a document's body	covid:3cf94195ef1930e200e2e391517d90644ab108a1#body_text
is schema:about of	named entity 'HCV' named entity 'Confocal microscopy' named entity 'exact' named entity 'barriers' named entity 'detailed' named entity 'hepatitis C virus' named entity 'SUSCEPTIBLE' named entity 'STABLE' named entity 'ACTING' named entity 'HEPATITIS C VIRUS' named entity 'RNA REPLICATION' named entity 'PROTEASE' named entity 'ANTIVIRALS' named entity 'LIFE' named entity 'WILD-TYPE' named entity 'VISUALIZATION' covid:arg/3cf94195ef1930e200e2e391517d90644ab108a1 named entity 'needed' named entity 'targets' named entity 'proteins' named entity 'drug' named entity 'genetic' named entity 'HIV' named entity 'RNA' named entity 'NS3' named entity 'NS5B' named entity 'resistance' named entity 'direct-acting' named entity 'susceptibility' named entity 'Transmission' named entity 'capsid proteins' named entity 'protease' named entity 'phosphoprotein' named entity 'HIV' named entity 'RNA replication' named entity 'Antiviral' named entity 'NS3' named entity 'phosphoprotein' named entity 'antivirals' named entity 'hepatitis C virus' named entity 'site-directed mutagenesis' named entity 'Leica' named entity 'NS3' named entity 'NS5A' named entity 'NS5A' named entity 'antivirals' named entity 'fluorescence in situ hybridization' named entity 'NS5A' named entity 'developed and tested' named entity 'NS5A' named entity 'Life Technologies' named entity 'HCV' named entity 'negative strand' named entity 'wild-type virus' named entity 'intracellular' named entity 'NS5A' named entity 'co-infected' named entity 'alleles' named entity 'confocal microscopy' named entity 'electron microscopy' named entity 'RNA' named entity 'NS3' named entity 'mycoplasma' named entity 'antibodies' named entity 'Michael Gale' named entity 'viruses' named entity 'phosphoprotein' named entity 'dominant-negative' named entity 'confocal microscope' named entity 'NS5A inhibitor' named entity 'drug target' named entity 'drug-resistant' named entity 'FISH' named entity 'genetically dominant' named entity 'penicillin' named entity 'combination therapies' named entity 'colocalization' named entity 'New England Biolabs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software